76. 下垂体性ゴナドトロピン分泌亢進症
[臨床試験数:25,薬物数:41(DrugBank:11),標的遺伝子数:3,標的パスウェイ数:10

Searched query = "Pituitary gonadotropin secretion hyperthyroidism", "Gonadotropin secreting pituitary adenoma", "Central precocious puberty", "Gonadotropin producing pituitary adenoma"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2000038202
2020-09-012020-09-13AMH combined INHB for the diagnosis of female central precocious pubertyAMH combined INHB for the diagnosis of female central precocious puberty Central precocious pubertyGold Standard:GnRHa provoctive test;Index test:Anti Mullerian hormone, Inhibin B;Capital Institute of PediatricsNULLRecruiting58FemaleTarget condition:150;Difficult condition:150China
2ChiCTR2000034464
2020-09-012020-07-05First Morning Voided Urinary Gonadotropin Measurements for the Early Screening, Diagnosis and Follow-up of CPP PatientsFirst Morning Voided Urinary Gonadotropin Measurements for the Early Screening, Diagnosis and Follow-up of CPP Patients Central precocious pubertyGold Standard:Clinical outcome by CPP diagnostic standards;Index test:morning urine GN;Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and TechnologyNULLPending612BothTarget condition:400;Difficult condition:6000China
3NCT03963752
(ClinicalTrials.gov)
August 15, 201922/5/2019Clinical Trial of Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western MedicineEvidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western MedicineIdiopathic Precocious PubertyDrug: Ziyinxiehuo Granules Herbs;Drug: Megestrol Acetate Tablet;Drug: Leuprorelin Acetate 3.75mg InjectionChildren's Hospital of Fudan UniversityNULLRecruiting5 Years8 YearsFemale164Phase 4China
4NCT03695237
(ClinicalTrials.gov)
October 24, 20182/10/2018A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)A Phase 3, Multicenter, Open-Label, Two-Part Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Depot Formulation in Children With Central Precocious Puberty (CPP)Central Precocious Puberty (CPP)Drug: Leuprolide Acetate (LA)AbbVieNULLActive, not recruiting2 Years11 YearsAll45Phase 3United States;Puerto Rico
5ChiCTR1800017120
2018-08-012018-07-12A real world study for the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girlsA real world study for the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girls. precocious pubertyCase series:rhGH therapy;The Children's Hospital, Zhejiang University School of MedicineNULLRecruiting312FemaleCase series:700;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6ChiCTR1800016768
2018-06-252018-06-22A real world study on the efficacy and safety of the combination therapy of GnRHa and recombinant human growth hormone in the treatment of central precocious puberty or rapid progressive adolescent girlsA real world study on the efficacy and safety of the combination therapy of GnRHa and rhGH in the treatment of central precocious puberty or rapid progressive adolescent girls Central precocious puberty or rapid progressive adolescenceCase series:GnRHa combined with rhGH;The Children's Hospital, Zhe Jiang University School of MedcineNULLRecruiting612FemaleCase series:700;China
7NCT02993926
(ClinicalTrials.gov)
June 24, 201713/12/2016A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese ParticipantsAn Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious PubertyPuberty, Central PrecociousDrug: Enantone;Drug: GnRH agonistTakedaNULLCompletedN/AN/AAll108China
8NCT02974270
(ClinicalTrials.gov)
June 201619/5/2016Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide AcetateAnalysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide AcetatePrecocious Puberty, CentralDrug: LeuprolideKyungpook National UniversityNULLRecruitingN/A9 YearsBoth100Phase 4Korea, Republic of
9NCT02811471
(ClinicalTrials.gov)
June 201621/6/2016Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious PubertyAn Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty—Part A and BCentral Precocious PubertyDrug: LeuprolideNemours Children's ClinicTolmar Inc.Recruiting2 Years9 YearsBoth5Phase 3United States
10NCT02452931
(ClinicalTrials.gov)
August 31, 20155/5/2015Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious PubertyAn Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious PubertyPrecocious Puberty, CentralDrug: Leuprolide Acetate 45 mgTolmar Inc.NULLCompleted2 Years9 YearsAll64Phase 3United States;Argentina;Canada;Chile;Mexico;New Zealand
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02427958
(ClinicalTrials.gov)
August 7, 201523/4/2015A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese ParticipantsAn Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious PubertyPuberty, PrecociousDrug: LeuprorelinTakedaNULLCompleted1 Year9 YearsAll307Phase 4China
12NCT03316482
(ClinicalTrials.gov)
June 11, 201512/10/2017Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious PubertyA Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious PubertyCentral Precocious PubertyDrug: Leuplin DPS 11.25mgJin Soon HwangNULLCompleted4 Years9 YearsAll58Phase 4Korea, Republic of
13NCT02920515
(ClinicalTrials.gov)
September 201216/8/2016Study of Comprehensive Diagnosis and Treatment for Children Precocious PubertyMulti-site Study of Comprehensive Treatment for Children Precocious PubertyCentral Precocious PubertyDrug: Triptorlin or Leuprorelin;Drug: Zhibo dihuang pills;Drug: Dabu ying pillsRuijin HospitalShanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua Hospital;Shanghai Children's Hospital;Shanghai Children's Medical Center;Xin Hua HospitalCompleted2 Years14 YearsFemale740Phase 4NULL
14NCT01467882
(ClinicalTrials.gov)
April 20127/11/2011Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious PubertyAn Open-label, Non-comparative, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Triptorelin Pamoate (Embonate) 22.5 mg 6-month Formulation in Patients Suffering From Central (Gonadotropin-dependent) Precocious PubertyCentral Precocious PubertyDrug: TriptorelinDebiopharm International SANULLCompleted2 Years9 YearsAll44Phase 3United States;Chile;Mexico
15NCT01634321
(ClinicalTrials.gov)
July 20113/7/2012The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious PubertyThe Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective StudyCentral Precocious PubertyDrug: Luphere depot 3.75mg(Leuprolide acetate 3.75mg)Daewoong Pharmaceutical Co. LTD.NULLCompleted4 Years9 YearsBoth63Phase 4Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT01278290
(ClinicalTrials.gov)
July 201014/1/2011Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in GirlsTriptorelin Acetate Utilization for the Early Diagnosis of Central Precocious Puberty (CPP) in Girls.Central Precocious Puberty;Sexual PrecocityDrug: Triptorelin acetate and Gonadorelin acetate;Drug: Gonadorelin acetate and Triptorelin acetateHospital de Niños R. Gutierrez de Buenos AiresNULLActive, not recruiting3 Years8 YearsFemale40Phase 4Argentina
17NCT00667446
(ClinicalTrials.gov)
December 200824/4/2008Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious PubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious PubertyPrecocious;Leuprolide Acetate;Luteinizing Hormone (LH);Gonadotrophin-releasing Hormone Agonist (GnRHa);Tanner Staging;Depot Formulation;Suppression of LH;Central Precocious Puberty (CPP);Gonadotrophin-releasing Hormone (GnRH);Lupron;GnRH Analog;Pediatrics Central Precocious PubertyDrug: Leuprolide Acetate 3 Month DepotAbbVie (prior sponsor, Abbott)NULLCompletedN/AN/AAll72Phase 3United States;Puerto Rico
18NCT00635817
(ClinicalTrials.gov)
June 20087/3/2008A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious PubertyA Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulations in Children With Central Precocious PubertyPuberty, PrecociousDrug: Leuprolide acetate 11.25 mg;Drug: Leuprolide acetate 30 mgAbbottNULLCompleted2 Years11 YearsAll84Phase 3United States;Puerto Rico
19NCT00438217
(ClinicalTrials.gov)
May 200621/2/2007Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty ChildrenAnalysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty ChildrenCentral Precocious PubertyDrug: Triptorelin (GnRH agonists);Drug: Leuprolide (GnRH agonists)University of PisaNULLRecruiting1 Year18 YearsBoth100Phase 4Italy
20NCT00779103
(ClinicalTrials.gov)
September 200422/10/2008Histrelin Subcutaneous Implant in Children With Central Precocious PubertyPhase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious PubertyCentral Precocious PubertyDrug: Histrelin Subcutaneous ImplantEndo PharmaceuticalsNULLCompleted2 Years10 YearsBoth36Phase 3NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT00660010
(ClinicalTrials.gov)
January 199115/4/2008Study of Lupron Depot In The Treatment of Central Precocious PubertyStudy of Lupron Depot In The Treatment of Central Precocious PubertyPuberty, PrecociousDrug: Lupron (leuprolide acetate)AbbottNULLCompletedN/A10 YearsAll55Phase 3United States
22EUCTR2014-004493-42-Outside-EU/EEA
(EUCTR)
03/12/2014A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature pubertyA Phase 3, Randomized, Multi-Center, Open-Label Study to Evaluate theEfficacy and Safety of Leuprolide Acetate 11.25 and 30 mg Formulationsin Children with Central Precocious Puberty Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
Product Name: Leuprolide acetate depot
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Abbvie previously known as AbbottNULLNAFemale: yes
Male: yes
80Phase 3United States;Puerto Rico
23EUCTR2015-001607-30-Outside-EU/EEA
(EUCTR)
24/04/2015Triptorelin 6-month formulation for children who mature too early because of a brain hormoneAn open-label, non-comparative, multicenter study on the efficacy, safety, and pharmacokinetics of triptorelin pamoate (embonate) 22.5 mg 6-month formulation in patients suffering from central (gonadotropin-dependent) precocious puberty - Triptorelin 6-month Formulation in Patients With Central Precocious Puberty Central Precocious Puberty
MedDRA version: 18.0;Level: PT;Classification code 10058084;Term: Precocious puberty;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Biological Phenomena [G16]
INN or Proposed INN: TRIPTORELIN
Other descriptive name: Triptorelin embonate, Triptorelin pamoate
Debiopharm International, S.A.NULLNAFemale: yes
Male: yes
44United States;Chile;Mexico
24EUCTR2014-004495-36-Outside-EU/EEA
(EUCTR)
28/11/2014A study of Lupron Depot Lupron Depot in treatment of central premature pubertyStudy of Lupron Depot in the Treatment of Central Precocious Puberty Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Abbvie previously known as AbbottNULLNAFemale: yes
Male: yes
55United States
25EUCTR2014-004494-16-Outside-EU/EEA
(EUCTR)
03/12/2014A clinical trial to determine safety and efficacy of Leuprolide Acetate 11.25mg and 30mg in children with central premature pubertyA 36 Month, Multi-Center, Open-Label Extension Study to Evaluate theSafety of Leuprolide Acetate 11.25 mg and 30 mg Formulations inChildren with Central Precocious Puberty Central Precocious Puberty
MedDRA version: 17.1;Level: LLT;Classification code 10073186;Term: Central precocious puberty;System Organ Class: 100000004860;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Trade Name: trade name depends on the source of the product
INN or Proposed INN: LEUPRORELIN ACETATE
Abbvie previously known as AbbottNULLNAFemale: yes
Male: yes
72United States;Puerto Rico